<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-240-8-13-19</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-3409</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Взаимосвязь витамин D-связывающего белка с неалкогольной жировой болезни печенью у больных сахарным диабетом 2 типа</article-title><trans-title-group xml:lang="en"><trans-title>The relationship of vitamin D-binding protein with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5727-1640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ягода</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Yagoda</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-7590-6201</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демурчева</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Demurcheva</surname><given-names>E. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6392-8461</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корой</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Koroy</surname><given-names>P. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-7244-3507</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудов</surname><given-names>Т. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudov</surname><given-names>T. R.</given-names></name></name-alternatives><email xlink:type="simple">timur222123@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Ставропольский государственный медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Stavropol State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение здравоохранения Ставропольского края «Краевой эндокринологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Endocrinological Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>08</month><year>2026</year></pub-date><volume>0</volume><issue>8</issue><fpage>13</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ягода А.В., Демурчева Е.О., Корой П.В., Дудов Т.Р., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Ягода А.В., Демурчева Е.О., Корой П.В., Дудов Т.Р.</copyright-holder><copyright-holder xml:lang="en">Yagoda A.V., Demurcheva E.O., Koroy P.V., Dudov T.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/3409">https://www.nogr.org/jour/article/view/3409</self-uri><abstract><p>Цель исследования. Изучить взаимосвязь содержания витамин D-связывающего белка (VDBP) в крови с клинико-лабораторными проявлениями неалкогольной жировой болезни печени (НАЖБП) у пациентов с сахарным диабетом 2 типа. Материалы и методы. Обследовано 80 больных сахарным диабетом 2 типа в возрасте от 33 до 69 лет (67 женщин, 13 мужчин). НАЖБП выявлена у 75,0% пациентов с сахарным диабетом 2 типа. Выраженный стеатоз печени наблюдался в 40,0% случаях НАЖБП, фиброз F3-4 - в 23,3%. Сывороточные уровни VDBP определялись методом иммуноферментного анализа. Результаты. Наличие НАЖБП на фоне сахарного диабета 2 типа характеризовалось более низким содержанием VDBP в крови. Биохимические синдромы патологии печени, а также проявления сахарного диабета (за исключением его длительности) не влияли на сывороточные уровни VDBP при НАЖБП. У пациентов с НАЖБП и ожирением, абдоминальным ожирением или дислипидемией определялась более низкая концентрация VDBP в крови. Показатели VDBP не зависели от наличия артериальной гипертензии и метаболического синдрома при НАЖБП. У больных, имевших выраженный стеатоз или фиброз печени F3-4, регистрировалось более низкое содержание VDBP в крови. Заключение. Таким образом, при НАЖБП, ассоциированной с сахарным диабетом 2 типа, наблюдается уменьшение содержания VDBP в крови, которое связано с длительностью диабета, наличием ожирения, абдоминального ожирения и дислипидемии. Случаи НАЖБП с выраженным стеатозом или тяжелым фиброзом/циррозом печени характеризуются более низкой сывороточной концентрацией VDBP.</p></abstract><trans-abstract xml:lang="en"><p>Aim of the investigation. To study the relationship of blood levels of vitamin D-binding protein (VDBP) with clinical and laboratory manifestations of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus. Materials and methods. The study included 80 patients with type 2 diabetes mellitus aged 33 to 69 years (67 women, 13 men). NAFLD was detected in 75.0% patients with type 2 diabetes mellitus. Severe liver steatosis was observed in 40.0% cases of NAFLD, fibrosis F3-4 in 23.3%. Serum levels of VDBP were determined by enzyme-linked immunosorbent assay. Results. The presence of NAFLD in patients with type 2 diabetes mellitus was characterized by lower blood levels of VDBP. Biochemical syndromes of liver pathology, as well as manifestations of diabetes mellitus (except for its duration) did not affect serum levels of VDBP in NAFLD. In patients with NAFLD and obesity, abdominal obesity or dyslipidemia, a lower concentration of VDBP in blood was determined. VDBP values did not depend on the presence of arterial hypertension and metabolic syndrome in NAFLD. Patients with severe liver steatosis or fibrosis F3-4 had lower blood levels of VDBP. Conclusion. Thus, in NAFLD associated with type 2 diabetes mellitus, there is a decrease of blood levels of VDBP, which is associated with the duration of diabetes, the presence of obesity, abdominal obesity and dyslipidemia. Cases of NAFLD with severe steatosis or severe fibrosis/liver cirrhosis are characterized by a lower serum concentration of VDBP.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>стеатоз печени</kwd><kwd>фиброз печени</kwd><kwd>витамин D-связывающий белок</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>liver steatosis</kwd><kwd>liver fibrosis</kwd><kwd>vitamin D-binding protein</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pop T. L., Sîrbe C., Benta G. et al. The Role of vitamin D and vitamin D binding protein in chronic liver diseases.Int. J. Mol. Sci. 2022; 23: 10705. doi: 10.3390/ijms231810705.</mixed-citation><mixed-citation xml:lang="en">Pop T. L., Sîrbe C., Benta G. et al. The Role of vitamin D and vitamin D binding protein in chronic liver diseases.Int. J. Mol. Sci. 2022; 23: 10705. doi: 10.3390/ijms231810705.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ravaioli F., Pivetti A., Di Marco L. et al. Role of vitamin D in liver disease and complications of advanced chronic liver disease.Int. J. Mol. Sci. 2022; 23: 9016. doi: 10.3390/ijms23169016.</mixed-citation><mixed-citation xml:lang="en">Ravaioli F., Pivetti A., Di Marco L. et al. Role of vitamin D in liver disease and complications of advanced chronic liver disease.Int. J. Mol. Sci. 2022; 23: 9016. doi: 10.3390/ijms23169016.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bouillon R., Schuit F., Antonio L. et al. Vitamin D binding protein: a historic overview. Front. Endocrinol. 2020; 10: 910. doi: 10.3389/fendo.2019.00910.</mixed-citation><mixed-citation xml:lang="en">Bouillon R., Schuit F., Antonio L. et al. Vitamin D binding protein: a historic overview. Front. Endocrinol. 2020; 10: 910. doi: 10.3389/fendo.2019.00910.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bikle D. D., Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front. Endocrinol. 2019; 10: 317. doi: 10.3390/ ijms24054642.</mixed-citation><mixed-citation xml:lang="en">Bikle D. D., Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front. Endocrinol. 2019; 10: 317. doi: 10.3390/ ijms24054642.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Viloria K., Nasteska D., Ast J. et al. GC-Globulin/vitamin D-binding protein is required for pancreatic α-cell adaptation to metabolic stress. Diabetes. 2023; 72: 275-289. doi: 10.2337/db22-0326.</mixed-citation><mixed-citation xml:lang="en">Viloria K., Nasteska D., Ast J. et al. GC-Globulin/vitamin D-binding protein is required for pancreatic α-cell adaptation to metabolic stress. Diabetes. 2023; 72: 275-289. doi: 10.2337/db22-0326.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Grama A., Burac L., Aldea C. O. et al. Vitamin D-binding protein (Gc-Globulin) in acute liver failure in children. Diagnostics. 2020; 10: 278. doi: 10.3390/diagnostics10050278.</mixed-citation><mixed-citation xml:lang="en">Grama A., Burac L., Aldea C. O. et al. Vitamin D-binding protein (Gc-Globulin) in acute liver failure in children. Diagnostics. 2020; 10: 278. doi: 10.3390/diagnostics10050278.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C. Z., Zhang J., Zhang L. et al. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J. Gastroenterol. 2021; 27 (3): 255-266. doi: 10.3748/wjg.v27.i3.255.</mixed-citation><mixed-citation xml:lang="en">Huang C. Z., Zhang J., Zhang L. et al. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J. Gastroenterol. 2021; 27 (3): 255-266. doi: 10.3748/wjg.v27.i3.255.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">El-masry A. S., Medhat A. M., El-Bendary M. et al. Vitamin D receptor rs3782905 and vitamin D binding protein rs7041 polymorphisms are associated with hepatocellular carcinoma susceptibility in cirrhotic HCV patients. BMC Med. Genomics. 2023; 16: 319. doi: 10.1186/s12920-023-01749-8.</mixed-citation><mixed-citation xml:lang="en">El-masry A. S., Medhat A. M., El-Bendary M. et al. Vitamin D receptor rs3782905 and vitamin D binding protein rs7041 polymorphisms are associated with hepatocellular carcinoma susceptibility in cirrhotic HCV patients. BMC Med. Genomics. 2023; 16: 319. doi: 10.1186/s12920-023-01749-8.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Xie C. N., Yue M., Huang P. et al. Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population. Gene. 2018; 679: 405-411. doi: 10.1016/j.gene.2018.09.021.</mixed-citation><mixed-citation xml:lang="en">Xie C. N., Yue M., Huang P. et al. Vitamin D binding protein polymorphisms influence susceptibility to hepatitis C virus infection in a high-risk Chinese population. Gene. 2018; 679: 405-411. doi: 10.1016/j.gene.2018.09.021.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lee S., Jin M. H., Yoon J.-H. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction. Sci. Rep. 2024; 14: 6714. doi: 10.1038/s41598-024-57380-9.</mixed-citation><mixed-citation xml:lang="en">Lee S., Jin M. H., Yoon J.-H. The contribution of vitamin D insufficiency to the onset of steatotic liver disease among individuals with metabolic dysfunction. Sci. Rep. 2024; 14: 6714. doi: 10.1038/s41598-024-57380-9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yagoda A. V., Koroy P. V., Demurcheva E. O. et al. Vitamin D as a marker of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medical News of North Caucasus. 2023; 18 (2): 131-135. doi: 10.14300/mnnc.2023.18028.</mixed-citation><mixed-citation xml:lang="en">Yagoda A. V., Koroy P. V., Demurcheva E. O. et al. Vitamin D as a marker of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medical News of North Caucasus. 2023; 18 (2): 131-135. doi: 10.14300/mnnc.2023.18028.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao X., Sun J., Xin S. et al. Correlation between serum 25 (OH) D levels with insulin resistance and metabolic associated fatty liver disease - a retrospective study based on chinese patients with newly diagnosed type 2 diabetes mellitus. Curr. Diabetes Rev. 2025; 21 (7): 56-66. doi: 10.2174/0115733998297640240611065605.</mixed-citation><mixed-citation xml:lang="en">Zhao X., Sun J., Xin S. et al. Correlation between serum 25 (OH) D levels with insulin resistance and metabolic associated fatty liver disease - a retrospective study based on chinese patients with newly diagnosed type 2 diabetes mellitus. Curr. Diabetes Rev. 2025; 21 (7): 56-66. doi: 10.2174/0115733998297640240611065605.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wang M., Wang M., Zhang R. et al. Influences of vitamin D levels and vitamin D-binding protein polymorphisms on nonalcoholic fatty liver disease risk in a Chinese population. Ann. Nutr. Metab. 2022; 78: 61-72. doi: 10.1159/000522193.</mixed-citation><mixed-citation xml:lang="en">Wang M., Wang M., Zhang R. et al. Influences of vitamin D levels and vitamin D-binding protein polymorphisms on nonalcoholic fatty liver disease risk in a Chinese population. Ann. Nutr. Metab. 2022; 78: 61-72. doi: 10.1159/000522193.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rinella M. E., Neuschwander-Tetri B. A., Siddiqui M. S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77 (5): 1797-1835. doi: 10.1097/HEP.0000000000000323.</mixed-citation><mixed-citation xml:lang="en">Rinella M. E., Neuschwander-Tetri B. A., Siddiqui M. S. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77 (5): 1797-1835. doi: 10.1097/HEP.0000000000000323.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sahu P., Chhabra P., Mehendale A. M. A comprehensive review on non-alcoholic fatty liver disease. Cureus. 2023; 15: e50159. doi: 10.7759/cureus.50159.</mixed-citation><mixed-citation xml:lang="en">Sahu P., Chhabra P., Mehendale A. M. A comprehensive review on non-alcoholic fatty liver disease. Cureus. 2023; 15: e50159. doi: 10.7759/cureus.50159.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Drapkina O. M., Evstifeeva S. E., Shalnova S. A. et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Cardiovascular Therapy and Prevention. 2025; 24 (2): 4316. (In Russ.) doi: 10.15829/1728-8800-2025-4316.@@ Драпкина О. М., Евстифеева С. Е., Шальнова С. А. и др. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025; 24 (2): 4316. doi: 10.15829/1728-8800-2025-4316.</mixed-citation><mixed-citation xml:lang="en">Drapkina O. M., Evstifeeva S. E., Shalnova S. A. et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Cardiovascular Therapy and Prevention. 2025; 24 (2): 4316. (In Russ.) doi: 10.15829/1728-8800-2025-4316.@@ Драпкина О. М., Евстифеева С. Е., Шальнова С. А. и др. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025; 24 (2): 4316. doi: 10.15829/1728-8800-2025-4316.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mantovani A., Taverna A., Cappelli D. et al. Long-term adverse effect of liver stiffness on glycaemic control in type 2 diabetic patients with nonalcoholic fatty liver disease: a pilot study.Int. J. Mol. Sci. 2022; 23: 12481. doi: 10.3390/ijms232012481.</mixed-citation><mixed-citation xml:lang="en">Mantovani A., Taverna A., Cappelli D. et al. Long-term adverse effect of liver stiffness on glycaemic control in type 2 diabetic patients with nonalcoholic fatty liver disease: a pilot study.Int. J. Mol. Sci. 2022; 23: 12481. doi: 10.3390/ijms232012481.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z. M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019; 71 (4): 793-801. doi: 10.1016/j.jhep.2019.06.021.</mixed-citation><mixed-citation xml:lang="en">Younossi Z. M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019; 71 (4): 793-801. doi: 10.1016/j.jhep.2019.06.021.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Choe Y., Lee Y. J., Kim J. H. et al. Free, bioavailable 25-hydroxyvitamin D levels and their association with diabetic ketoacidosis in children with type 1 diabetes at diagnosis. Front. Endocrinol. 2022; 13: 997631. doi: 10.3389/fendo.2022.997631.</mixed-citation><mixed-citation xml:lang="en">Choe Y., Lee Y. J., Kim J. H. et al. Free, bioavailable 25-hydroxyvitamin D levels and their association with diabetic ketoacidosis in children with type 1 diabetes at diagnosis. Front. Endocrinol. 2022; 13: 997631. doi: 10.3389/fendo.2022.997631.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cave E. M., Bhola S., Crowther N. J. et al. The association of vitamin D binding protein levels and genotypes with type 1 diabetes in the black South African population. BMC Endocr. Disord. 2022; 22 (1): 182. doi: 10.1186/s12902-022-01097-1.</mixed-citation><mixed-citation xml:lang="en">Cave E. M., Bhola S., Crowther N. J. et al. The association of vitamin D binding protein levels and genotypes with type 1 diabetes in the black South African population. BMC Endocr. Disord. 2022; 22 (1): 182. doi: 10.1186/s12902-022-01097-1.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H. Y., Lee Y. A., Jung H. W. et al. A lack of association between vitamin D-binding protein and 25-hydroxyvitamin D concentrations in pediatric type 1 diabetes without microalbuminuria. Ann. Pediatr. Endocrinol. Metab. 2017; 22 (4): 247-252. doi: 10.6065/apem.2017.22.4.247.</mixed-citation><mixed-citation xml:lang="en">Kim H. Y., Lee Y. A., Jung H. W. et al. A lack of association between vitamin D-binding protein and 25-hydroxyvitamin D concentrations in pediatric type 1 diabetes without microalbuminuria. Ann. Pediatr. Endocrinol. Metab. 2017; 22 (4): 247-252. doi: 10.6065/apem.2017.22.4.247.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao X., Li B., Li X. et al. Association of serum 25-hydroxyvitamin D levels, vitamin D-binding protein levels, and diabetes mellitus: two-sample Mendelian randomization. Medicine (Baltimore). 2024; 103 (20): e38219. doi: 10.1097/MD.0000000000038219.</mixed-citation><mixed-citation xml:lang="en">Zhao X., Li B., Li X. et al. Association of serum 25-hydroxyvitamin D levels, vitamin D-binding protein levels, and diabetes mellitus: two-sample Mendelian randomization. Medicine (Baltimore). 2024; 103 (20): e38219. doi: 10.1097/MD.0000000000038219.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gotlieb N., Tachlytski I., Lapidot Y. et al. Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production. Mol. Med. 2018; 24: 53. doi: 10.1186/s10020-018-0055-0.</mixed-citation><mixed-citation xml:lang="en">Gotlieb N., Tachlytski I., Lapidot Y. et al. Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin D-dependent inhibition of viral transcription and production. Mol. Med. 2018; 24: 53. doi: 10.1186/s10020-018-0055-0.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Hu Y. C., Wang W. W., Jiang W. Y. et al. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19: 84. doi: 10.1186/s12876-019-1004-2.</mixed-citation><mixed-citation xml:lang="en">Hu Y. C., Wang W. W., Jiang W. Y. et al. Low vitamin D levels are associated with high viral loads in patients with chronic hepatitis B: a systematic review and meta-analysis. BMC Gastroenterol. 2019; 19: 84. doi: 10.1186/s12876-019-1004-2.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Abdella N. A., Mojiminiyi O. A. Vitamin D-binding protein clearance ratio is significantly associated with glycemic status and diabetes complications in a predominantly vitamin D-deficient population. J. Diabetes Res. 2018; 2018: 6239158. doi: 10.1155/2018/6239158.</mixed-citation><mixed-citation xml:lang="en">Abdella N. A., Mojiminiyi O. A. Vitamin D-binding protein clearance ratio is significantly associated with glycemic status and diabetes complications in a predominantly vitamin D-deficient population. J. Diabetes Res. 2018; 2018: 6239158. doi: 10.1155/2018/6239158.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Thanapirom K., Suksawatamnuay S., Sukeepaisarnjaroen W. et al. Vitamin D-binding protein gene polymorphism predicts pegylated interferon-related HBsAg seroclearance in HBeAg-negative thai chronic hepatitis B patients: a multicentre study. Asian Pac. J. Cancer Prev. 2019; 20: 1257-1264. doi: 10.31557/APJCP.2019.20.4.1257.</mixed-citation><mixed-citation xml:lang="en">Thanapirom K., Suksawatamnuay S., Sukeepaisarnjaroen W. et al. Vitamin D-binding protein gene polymorphism predicts pegylated interferon-related HBsAg seroclearance in HBeAg-negative thai chronic hepatitis B patients: a multicentre study. Asian Pac. J. Cancer Prev. 2019; 20: 1257-1264. doi: 10.31557/APJCP.2019.20.4.1257.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Karuwanarint P., Phonrat B., Tungtrongchitr A. et al. Vitamin D-binding protein and its polymorphisms as a predictor for metabolic syndrome. Biomark. Med. 2018; 12 (5): 465-473. doi: 10.2217/bmm-2018-0029.</mixed-citation><mixed-citation xml:lang="en">Karuwanarint P., Phonrat B., Tungtrongchitr A. et al. Vitamin D-binding protein and its polymorphisms as a predictor for metabolic syndrome. Biomark. Med. 2018; 12 (5): 465-473. doi: 10.2217/bmm-2018-0029.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pelczyńska M., Grzelak T., Sperling M. et al. Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components. Arch. Med. Sci. 2017; 13 (4): 745. doi: 10.5114/aoms.2016.58594.</mixed-citation><mixed-citation xml:lang="en">Pelczyńska M., Grzelak T., Sperling M. et al. Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components. Arch. Med. Sci. 2017; 13 (4): 745. doi: 10.5114/aoms.2016.58594.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Setayesh L., Casazza K., Moradi N. et al. Association of vitamin D-binding protein and vitamin D3 with insulin and homeostatic model assessment (HOMA-IR) in overweight and obese females. BMC Res. Notes. 2021; 14 (1): 193. doi: 10.1186/s13104-021-05608-6.</mixed-citation><mixed-citation xml:lang="en">Setayesh L., Casazza K., Moradi N. et al. Association of vitamin D-binding protein and vitamin D3 with insulin and homeostatic model assessment (HOMA-IR) in overweight and obese females. BMC Res. Notes. 2021; 14 (1): 193. doi: 10.1186/s13104-021-05608-6.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kuliczkowska-Plaksej J., Pasquali R., Milewicz A. et al. Serum vitamin D binding protein level associated with metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. Horm. Metab. Res. 2019; 51 (1): 54-61. doi: 10.1055/a-0759-7533.</mixed-citation><mixed-citation xml:lang="en">Kuliczkowska-Plaksej J., Pasquali R., Milewicz A. et al. Serum vitamin D binding protein level associated with metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. Horm. Metab. Res. 2019; 51 (1): 54-61. doi: 10.1055/a-0759-7533.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Fawzy M. S., Abu AlSel B. T. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients. J. Diabetes Res. 2018; 2018: 8517929. doi: 10.1155/2018/8517929.</mixed-citation><mixed-citation xml:lang="en">Fawzy M. S., Abu AlSel B. T. Assessment of vitamin D-binding protein and early prediction of nephropathy in type 2 Saudi diabetic patients. J. Diabetes Res. 2018; 2018: 8517929. doi: 10.1155/2018/8517929.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Hidalgo-Bravo A., Rivera-Paredez B., León-Reyes G. et al. Unravelling the contribution of the rs7041 and rs4588 polymorphisms of the GC gene and serum VDBP levels for developing metabolic syndrome in the Mexican population.Int. J. Mol. Sci. 2022; 23 (18): 10581. doi: 10.3390/ijms231810581.</mixed-citation><mixed-citation xml:lang="en">Hidalgo-Bravo A., Rivera-Paredez B., León-Reyes G. et al. Unravelling the contribution of the rs7041 and rs4588 polymorphisms of the GC gene and serum VDBP levels for developing metabolic syndrome in the Mexican population.Int. J. Mol. Sci. 2022; 23 (18): 10581. doi: 10.3390/ijms231810581.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Delanghe J. R., Clement F., Speeckaert M. M. et al. Vitamin D binding protein polymorphism is associated with body weight in females. Horm. Mol. Biol. Clin. Investig. 2025; 46 (3): 133-138. doi: 10.1515/hmbci-2025-0028.</mixed-citation><mixed-citation xml:lang="en">Delanghe J. R., Clement F., Speeckaert M. M. et al. Vitamin D binding protein polymorphism is associated with body weight in females. Horm. Mol. Biol. Clin. Investig. 2025; 46 (3): 133-138. doi: 10.1515/hmbci-2025-0028.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao K., Zhang D.-C., Hu Y. et al. Potential roles of vitamin D binding protein in attenuating liver injury in sepsis. Mil. Med. Res. 2022; 9: 4. doi: 10.1186/s40779-022-00365-4.</mixed-citation><mixed-citation xml:lang="en">Xiao K., Zhang D.-C., Hu Y. et al. Potential roles of vitamin D binding protein in attenuating liver injury in sepsis. Mil. Med. Res. 2022; 9: 4. doi: 10.1186/s40779-022-00365-4.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
